<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00435669</url>
  </required_header>
  <id_info>
    <org_study_id>CA182-008</org_study_id>
    <nct_id>NCT00435669</nct_id>
  </id_info>
  <brief_title>A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664)</brief_title>
  <official_title>Mass Balance, Pharmacokinetics and Metabolism of [14C]BMS-582664 Prodrug of BMS-540215, in Subjects With Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to determine the mass balance, pharmacokinetics, metabolism, and
      routes and extent of elimination of BMS-582664
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absorption</measure>
    <time_frame>Determined by PK measurement collected on Day 1 at timepoints 0 (predose) 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 18 and 24 hour. Continue daily PK collection on Day 2 to Day 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution</measure>
    <time_frame>Determined by PK measurement collected on Day 1 at timepoints 0 (predose) 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 18 and 24 hour. Continue daily PK collection on Day 2 to Day 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolism</measure>
    <time_frame>Determined by PK measurement collected on Day 1 at timepoints 0 (predose) 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 18 and 24 hour. Continue daily PK collection on Day 2 to Day 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination of BMS-582664</measure>
    <time_frame>Determined by PK measurement collected on Day 1 at timepoints 0 (predose) 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 18 and 24 hour. Continue daily PK collection on Day 2 to Day 10</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess safety and tolerability of BMS-582664 800 mg administered daily in Part B</measure>
    <time_frame>at last patient last visit</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">4</enrollment>
  <condition>Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brivanib</intervention_name>
    <description>Oral Solution, Oral, 800 mg, X1 on Day 1, 10 D for ADME</description>
    <other_name>BMS-582664</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brivanib</intervention_name>
    <description>Tablet, Oral, Brivanib 800 mg, QD, until progression</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologic/cytologic diagnosis of advanced or metastatic solid tumors

          -  ECOG 0-2

          -  4/6 weeks since prior therapy

        Exclusion Criteria:

          -  Brain metastases

          -  Secondary primary malignancy

          -  Thromboembolic disease requiring full anticoagulation within 6 months

          -  Inability to swallow or absorb oral therapy

          -  Uncontrolled hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>July 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2007</study_first_submitted>
  <study_first_submitted_qc>February 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2007</study_first_posted>
  <last_update_submitted>January 21, 2009</last_update_submitted>
  <last_update_submitted_qc>January 21, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 22, 2009</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>Bristol-Myers Squibb</organization>
  </responsible_party>
  <keyword>Advanced or metastatic solid tumors</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

